Sign inJoin waitlistJoin the waitlist

Markus Y Mapara

Director, Adult Blood and Marrow Transplantation Program · Columbia University Medical Center

Credentials: · · · · ·

History

Adult Blood and Marrow Transplantation Program · Columbia University Medical Center
Present
Columbia University Medical Center
Present

Humboldt University, Faculty of Medicine
Transplantation Biology Research Center of the Massachusetts General Hospital at the Harvard Medical School
Humboldt University, Faculty of Medicine
University of Heidelberg
University of Heidelberg Medical School/Germany

Research

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
New England Journal of Medicine · 2021 · 1,440 citations
Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells
Journal of Clinical Investigation · 1997 · 634 citations
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an…
Journal of Clinical Oncology · 2013 · 376 citations

Suzanne Lentzsch
46 papers
Divaya Bhutani
19 papers
Ran Reshef
17 papers
Rajshekhar Chakraborty
15 papers
Mathew Maurer
13 papers
Amer Assal
11 papers
Jai Radhakrishnan
10 papers
HF
Haydar Frangoul
7 papers
Adrienne Mishkin
6 papers
David Roodman
6 papers
Akshay Sharma
5 papers
Marcus Pereira
5 papers

Grants

Short Term Training Grant
National Heart, Lung, and Blood Institute · T35
PI · $257.9K · Columbia University Health Sciences
1981–2031
Molecular Oncology Training Program
National Cancer Institute · T32
PI · $1.6M · Columbia University Health Sciences
2016–2031
Binding of MMP13 to Immune Checkpoint Receptor PD-1H Links Bone Disease with Immune Suppression in Multiple Myeloma
National Cancer Institute · R01
PI · $2.4M · Columbia University Health Sciences
2021–2027
Graft Engineering of Allogeneic Hematopoietic Stem Cell Products with Molecular Cascades
National Institute of Biomedical Imaging and Bioengineering · R01
PI · $2.6M · Columbia University Health Sciences
2018–2022

Clinical trials

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
Principal investigator · Recruiting · Phase 1
Columbia University
2025–2032
Siplizumab for Sickle Cell Disease Transplant
Principal investigator · Terminated · Phase 1, Phase 2
Columbia University
2023–2025
Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease
Principal investigator · Terminated · Phase 1
Columbia University
2020–2021
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma
Principal investigator · Completed · Phase 1
Applied Molecular Evolution
2006–2009